CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs - ScienceDirect
Por um escritor misterioso
Descrição
Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities, Journal of Nanobiotechnology
PDF) CRISPR/Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in Dominant Optic Atrophy patient-derived iPSCs
PDF) CRISPR/Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in Dominant Optic Atrophy patient-derived iPSCs
NIR-II/CRISPR-Cas9 system optogenetic regulation of genome editing.
CRISPRi gene modulation and all-optical electrophysiology in post-differentiated human iPSC-cardiomyocytes
Co-opting regulation bypass repair as a gene-correction strategy for monogenic diseases: Molecular Therapy
Loss of OPA1 disturbs cellular calcium homeostasis and sensitizes for excitotoxicity
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Gene augmentation prevents retinal degeneration in a CRISPR/Cas9-based mouse model of PRPF31 retinitis pigmentosa
A Genome-wide CRISPR Death Screen Identifies Genes Essential for Oxidative Phosphorylation - ScienceDirect
